-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $20

Benzinga·11/16/2026 18:51:06
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $26 to $20.